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Abstract
Cyclin-dependent kinase-like kinases (CLKs) are dual specificity protein kinases that phosphorylate Serine/Arginine-rich (SR)
proteins involved in pre-mRNA processing. Four CLKs, termed PfCLK-1-4, can be identified in the human malaria parasite
Plasmodium falciparum, which show homology with the yeast SR protein kinase Sky1p. The four PfCLKs are present in the
nucleus and cytoplasm of the asexual blood stages and of gametocytes, sexual precursor cells crucial for malaria parasite
transmission from humans to mosquitoes. We identified three plasmodial SR proteins, PfSRSF12, PfSFRS4 and PfSF-1, which
are predominantly present in the nucleus of blood stage trophozoites, PfSRSF12 and PfSF-1 are further detectable in the
nucleus of gametocytes. We found that recombinantly expressed SR proteins comprising the Arginine/Serine (RS)-rich
domains were phosphorylated by the four PfCLKs in in vitro kinase assays, while a recombinant PfSF-1 peptide lacking the
RS-rich domain was not phosphorylated. Since it was hitherto not possible to knock-out the pfclk genes by conventional
gene disruption, we aimed at chemical knock-outs for phenotype analysis. We identified five human CLK inhibitors,
belonging to the oxo-b-carbolines and aminopyrimidines, as well as the antiseptic chlorhexidine as PfCLK-targeting
compounds. The six inhibitors block P. falciparum blood stage replication in the low micromolar to nanomolar range by
preventing the trophozoite-to-schizont transformation. In addition, the inhibitors impair gametocyte maturation and
gametogenesis in in vitro assays. The combined data show that the four PfCLKs are involved in phosphorylation of SR
proteins with essential functions for the blood and sexual stages of the malaria parasite, thus pointing to the kinases as
promising targets for antimalarial and transmission blocking drugs.
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Introduction
The protozoan parasite Plasmodium falciparum is responsible
for more than 600,000 fatal cases caused by the tropical disease
malaria per annum [1]. During life cycle progression from humans
to mosquitoes, P. falciparum switches between stages with high
replication rates and ones arrested in their cell cycle and also
passes through a phase of sexual reproduction. These rapid
transformations require fine-tuned mechanisms of gene expres-
sion, and the importance of post-transcriptional regulation of gene
expression in Plasmodium parasites has previously been highlight-
ed [2]. These include the alternative splicing (AS) of pre-mRNA,
enabling the parasite to express functionally different protein
isoforms. Two genome-wide studies implied that more than 200
AS events occur during blood stage replication of P. falciparum
[3,4].
AS involves multiple auxiliary factors that control splice site
selection, spliceosome assembly as well as the splicing reaction
[5,6]. One group of proteins regulating the selection of alterna-
tively spliced exonic or intronic pre-mRNA sequences is that of
Serine/Arginine-rich (SR) proteins [5]. SR proteins usually
contain a RNA recognition motif and an Arginine/Serine-rich
(RS) domain required for protein-protein interactions during
splicing. SR proteins are phosphorylated by several protein kinase
families, including the cyclin-dependent kinase-like kinases (CLKs)
[7,8].
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The genome of P. falciparum encodes four members of the
CLK family, which were previously termed PfCLK-1-4 [9–11].
For PfCLK-1 (originally described as LAMMER kinase) [12] and
PfCLK-2 homologies with the yeast SR protein kinase Sky1p were
shown [11]. Both kinases are expressed in the P. falciparum blood
stages and phosphorylate a number of substrates in vitro,
including the Sky1p substrate, SR protein Npl3p, and the
plasmodial alternative splicing factor PfASF-1 [11]. Similarly,
PfCLK-4 (also known as SRPK1) is expressed in the blood stages
of P. falciparum, where it phosphorylates the plasmodial protein
SR1 [13], an AS factor required for parasite proliferation [14].
Previous reverse genetics studies indicated an important role of the
four PfCLKs for completion of the asexual replication cycle, since
disruption of the respective genes was not achievable, while the
loci were amenable to a modification that does not cause loss-of-
function [11,15].
Here we aimed to investigate the involvement of the four
PfCLKs in the phosphorylation of plasmodial SR proteins and to
determine the crucial role of the kinases for the blood and
transmission stages of P. falciparum via chemical knock-outs using
a variety of newly identified CLK inhibitors.
Materials and Methods
Gene IDs and data analysis
The following PlasmoDB gene identifiers (plasmodb.org;
previous IDs set in brackets) [16,17] are assigned to the CLKs
and SR proteins investigated in this study (shown in Fig. 1):
PfCLK-1, PF3D7_1445400 (PF14_0431); PfCLK-2,
PF3D7_1443000 (PF14_0408); PfCLK-3, PF3D7_1114700
(PF11_0156); PfCLK-4, PF3D7_0302100 (PFC0105w); PfPKRP,
PF3D7_0311400 (PFC0485w); PfSFRS4, PF3D7_1022400
(PF10_0217); PfSRSF12, PF3D7_0503300 (PFE0160c); PfSF-1,
PF3D7_1321700 (MAL13P1.120).
Bioinformatics
The following computer programs and databases were used for
the in silico studies: For gene sequence annotation, PlasmoDB
(www.plasmodb.org) [16,17], the SMART program (www.smart.
embl-heidelberg.de) [18,19] and NCBI sequence analysis software
and databanks [20] were used. Multiple sequence alignment
involved programs ClustalW (www.ebi.ac.uk/clustalw) [21] and
Clone Manager 9, and formatting of multiple sequence alignments
was pursued according to standard methods (espript.ibcp.fr).
CLK inhibitors
Chlorhexidine (CHX) was purchased from Sigma-Aldrich. The
spiropiperidino-b-carbolines KH-CARB-10, KH-CARB-11, and
KH-CARB-13xHCl were prepared as described previously
(Fig. 2A) [22]. The aminopyrimidyl b-carboline C-117 and the
aminopyrimidyl carbazole gea-27 were prepared starting from
known methyl ketones as precursors (Fig. 2B). In short, treatment
of 1-acetyl-b-carboline (1; see Fig. 2B) [23] with tert-butoxy-
bis(dimethylamino)methane (Bredereck’s reagent) in refluxing
dimethylformamide, followed by addition of 4-methylpiperazine-
1-carboxamidinium sulfate and potassium carbonate gave the
target compound C-117 in good yield in one single operation [24].
For the synthesis of gea-27 the acetylcarbazole (2) [25] was
protected at the pyrrole nitrogen with the SEM (2-(trimethylsilyl)-
ethoxymethyl) group to give (3), then heated with Bredereck’s
reagent and subsequently with guanidinium carbonate and
potassium carbonate. The resulting aminopyrimidine intermediate
was deprotected with HF to give the target compound. Syntheses
of C-117 and gea-27 are described in detail in (Methods S1). All
Figure 1. Schematic of the plasmodial PfCLKs and SR proteins. A. Domain structures of the PfCLKs. B. Domain structures of the plasmodial SR
proteins investigated in this study.
doi:10.1371/journal.pone.0105732.g001
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inhibitors were prepared as 100 mM stock solutions in dimethyl
sulfoxide (DMSO).
Parasite culture
Asexual blood stage parasites and gametocytes of the P.
falciparum NF54 [26] isolate and asexual blood stage parasites
of the P. falciparum strains 3D7 [27] and F12 [28] were cultivated
in human erythrocytes in vitro as described [29–31]. The
following parasite lines were obtained through the MR4 as part
of the BEI Resources Repository, NIAID, NIH: Plasmodium
falciparum NF54, MRA-1000, deposited by M Dowler, Walter
Reed Army Institute of Research and Plasmodium falciparum
3D7, MRA-102, deposited by DJ Carucci. Parasite line F12 was
kindly provided by Pietro Alano, Istituto Superiore di Sanità,
Rome. Human A+ erythrocyte sediment and serum were
purchased from the University Hospital Aachen, Germany (PO
no. DKG-NT 9748). The erythrocyte and sera samples were
pooled and the donors remained anonymous; the work on human
blood was approved by the ethics commission of RWTH Aachen
University. RPMI medium 1640 (Gibco) was supplemented with
either A+ human serum (for NF54 and F12) or 0.5% Albumax II
(for 3D7; Invitrogen), hypoxanthine (Sigma-Aldrich) and genta-
micin (Invitrogen) and cultures were maintained at 37uC in an
atmosphere of 5% O2, 5% CO2, 90% N2. Gametogenesis was
induced by incubating mature gametocyte cultures in 100 mM
xanthurenic acid for 15 min at room temperature (RT) [32,33].
For synchronization, parasite cultures with 3–4% ring stages were
centrifuged to obtain the pellet, which was resuspended in five
times pellet’s volume of 5% prewarmed sorbitol (AppliChem) in
RPMI medium (Invitrogen) and incubated at RT for 10 min [34].
The cells were washed once with RPMI medium to remove the
sorbitol, diluted to 5% vol. hematocrit and cultured as described
above.
Recombinant protein expression
Recombinant proteins were expressed as fusion proteins either
with a glutathione S-transferase (GST)-tag using the pGEX 4T1
vector (Amersham Bioscience) or with a maltose binding protein
(MaBP)-tag using the pIH-vector (kindly provided by Kim
Williamson, Loyola University Chicago). Cloning into the
pGEX4T1 vector was mediated by EcoRI/NotI restriction sites
added at the ends of PCR-amplified gene fragments and cloning
into the pIH-vector was mediated by EcoRI/SalI restriction sites.
Primers used for cloning are listed in (Table S1). Recombinant
proteins were expressed in E. coli BL21 (DE3) RIL according to
the manufacturer’s protocol (Stratagene). GST-fusion proteins
were purified from bacterial extracts using glutathione-sepharose
according to the manufacturer’s protocol (GE Healthcare). MaBP-
tagged recombinant proteins were purified using amylose resin
(New England Biolabs) as described previously [35] with following
modifications of the procedure: pelleted bacteria were directly
resuspended in lysis buffer containing complete, EDTA-free
protease inhibitor cocktail (Roche), incubated on ice for 20 min
and homogenized by 4 min of sonication (50 cycles/50%
intensity). DNAse treatment was not deployed. Amylose-bound
fusion protein was eluted during batch purification according to
the manufacturer’s protocol.
Generation of antisera
GST-tagged recombinant PfPKRP protein was prepared from
bacterial inclusion bodies as described previously [36], while GST-
tagged recombinant PfCLK-4 and MaBP-tagged recombinant SR
proteins were purified via chromatography as described above.
Specific immune sera against the recombinant fragments of the
respective kinases and the SR-proteins were generated by the
initial immunization of 6 weeks-old female NMRI mice (Charles
River Laboratories) with 100 mg recombinant protein emulsified in
Freund’s incomplete adjuvant (Sigma-Aldrich) followed by a boost
with 30 mg recombinant protein 4 weeks after immunization. Mice
were anesthetized by intraperitoneal injection of a mixture of
ketamine and xylazine according to the manufacturer’s protocol
(Sigma-Aldrich), and immune sera were collected 10 days after the
second immunization (boost) via heart puncture. Following sera
collection the anesthetized mice were sacrificed via severing the
cervical spine. The immune sera of three mice immunized with the
same antigen were pooled; sera of three non-immunized mice
were used as negative control. The antisera recognized the cognate
recombinant protein (data not shown). Experiments for the
generation of antisera in mice were approved by the animal
welfare committees of the government of Lower Franconia,
Germany (ref. no. 55.2-2531.01-58/09), and of the District
Council of Cologne, Germany (ref. no. 84-02.05.30.12.097
TVA). The generation of mouse anti-PfCLK-1 and anti-PfCLK-
2 antisera was described previously [11]. As a second source of
PfCLK1-specific antibody, sera directed against the peptide
sequence NRTKTSDTEDKKER (AA508-521) upstream of the
catalytic domain were produced by immunization of two rabbits
(Biogenes, Berlin). Specific PfCLK-3 rat antibody was raised by
immunizing rats with peptide YKSKHEENSPDGDSY (AA30-44)
and purified by protein G as described [15].
Indirect immunofluorescence assay
Parasite preparations for indirect immunofluorescence assays
(IFAs) included mixed asexual blood stages of P. falciparum F12
strain or mature gametocytes of NF54 strain. Preparations were
Figure 2. Chemical structures of CLK inhibitors. A. Structures of
the spiropiperidino-b-carbolines KH-CARB-10, KH-CARB-11, and KH-
CARB-13xHCl. B. Synthesis of the aminopyrimidyl b-carboline C-117 and
the aminopyrimidyl carbazole gea-27.
doi:10.1371/journal.pone.0105732.g002
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air-dried on slides and fixed for 10 min either in 280uC methanol
or, to label the SR proteins, with 4% paraformaldehyde (pH 7.4).
For membrane permeabilization and blocking of non-specific
binding, methanol-fixed cells were incubated in 0.01% saponin,
0.5% bovine serum albumin faction V (BSA) and 1% neutral goat
serum (Sigma-Aldrich) in PBS for 30 min. Paraformaldehyde-
fixed samples were permeabilized with 0.1% vol. Triton X-100
and 125 mM glycine (Carl Roth) in PBS for 30 min, followed by
blocking with 3% BSA in PBS for 1 h. Preparations were then
incubated for 2 h at 37uC with rat antisera against PfCLK-3 or
mouse antisera against PfCLK-4 and the SR proteins. Antisera
dilutions of 1:50 to 1:100 were used. Binding of primary antibody
was visualized using fluorophore-conjugated goat anti-rat or anti-
mouse antibodies (Alexa Fluor 488; Molecular Probes). Asexual
blood stage parasites were highlighted with rabbit immune sera
specific for the merozoite surface protein PfMSP-1 (ATCC), while
gametocytes were highlighted with rabbit anti-Pfs230 antisera,
followed by incubation with fluorophore-conjugated goat anti-
rabbit antibodies (Alexa Fluor 594; Molecular Probes). In the co-
localization experiments, PfCLK-1 was immunolabelled in the
young schizont stages using the respective rabbit antisera (dilution
of 1:100) in combination with Alexa Fluor 594 goat anti-rabbit
antibody. Nuclei were highlighted by incubating the specimens
with Hoechst nuclear stain 33342 (Molecular Probes) for 1 min.
Labelled specimens were examined by confocal laser scanning
microscopy using a LEICA TCS SP5 or an Olympus BX41
fluorescence microscope in combination with a ProgRes Speed
XT5 camera. Digital images were processed using Adobe
Photoshop CS software. Quantifications of schizonts (highlighted
by anti-MSP-1 antisera or Hoechst nuclear stain) or gametocytes
(highlighted by anti-Pfs230 antisera) positive for the PfCLKs or the
SR proteins were performed in triplicate (40–60 parasites counted
per well).
Western blot analysis
Mixed blood stage parasites of P. falciparum strain NF54 were
harvested and treated with 0.15% saponin for erythrocyte lysis.
Parasite nuclear pellet and cytoplasmic fractions were prepared as
described previously [11]. Parasite pellets, the nuclear pellet and
cytoplasmic fractions as well as pellets of non-infected erythrocytes
or immunoprecipitated bead-bound proteins (see below) were
washed with PBS, resuspended and sonicated in lysis buffer
(20 mM Tris-HCl pH 8.0, 10 mM EDTA pH 8.0, 400 mM NaCl,
1 mM PSMF, 10 mM b-glycerophosphate, 10 mM NaF, 0.25%
Triton X-100) supplemented with a protease inhibitor cocktail
(Roche Diagnostics). Parasite proteins were separated by SDS-
PAGE electrophoresis and transferred to Hybond ECL nitrocel-
lulose membrane (Amersham Biosciences) according to the
manufacturer’s protocol. Membranes were blocked for non-
specific binding by incubation in Tris-buffered saline containing
5% skim milk and 1% BSA, followed by immune recognition for
2 h at RT with rabbit anti-PfCLK-1, rat anti-PfCLK-3 or mouse
anti-PfCLK-4, anti-Pf39 [36] or anti-Pfalpha-5 antisera [37]. For
control sera from non-immunized animals were used. After
washing, membranes were incubated for 1 h at RT with an
alkaline phosphatase-conjugated secondary antibody (Sigma-
Aldrich) and developed in a solution of nitroblue tetrazolium
chloride (NBT) and 5-bromo-4-chloro-3-indoxyl phosphate (BCIP;
Sigma-Aldrich) for 5–30 min. Scanned blots were processed using
Adobe Photoshop CS software.
Immunoprecipitation assay
Mixed P. falciparum NF54 asexual blood stage parasites were
harvested and treated with 0.15% saponin for erythrocyte lysis.
Parasite pellets were resuspended in 150 ml lysis buffer and
sonicated with 50% amplitude and 50 cycles followed by
centrifugation at 13,0006g at 4uC for 10 min. Pre-clearing of
lysates was carried out by consecutive incubation with 5% vol.
serum of non-immunized mouse, rabbit or rat, and 20 ml of
protein G-beads (Santa Cruz Biotechnology) for 30 min each at
4uC. Lysates were then incubated for 2 h with the respective
kinase-specific antisera (see above) or anti-Pf39 antisera under
constant agitation at 4uC. Subsequently the antibody-antigen
complexes were incubated over night with 20 ml of protein G-
beads at 4uC. The beads were centrifuged, washed four times with
16PBS and were subsequently deployed in Western blotting (see
above) or the kinase activity assay (see below). Gels were stained
after resolving with Coomassie Blue Stain and scanned for digital
processing using Adobe Photoshop CS software.
Kinase activity assay
Kinase reactions of 30 ml were carried out in a standard kinase
buffer (20 mM Tris-HCl, pH 7.5, 20 mM MgCl2, 2 mM MnCl2,
10 mM NaF, 10 mM b-glycerophosphate, 10 mM ATP and
0.1 MBq [c-32P]-ATP), using immunoprecipitated endogenous
kinases as well as 5–10 mg of the respective substrate. When the
PfPKRP-specific immunoprecipitates were used in the assays,
50 mM of bovine calmodulin (CaM; dissolved in water; CalBio-
chem) were added to the reaction. Recombinantly expressed His6-
tagged protein kinase 6 (rPK6), purified as previously reported
[38], was used as a positive control for the kinase activity assay
utilizing exogenous substrates. For testing of the CLK inhibitors,
sorbitol-synchronized ring stages were incubated with the inhib-
itors at IC50 concentrations for 12 h before immunoprecipitation.
In the assays, exogenous substrates (histone H1, myelin basic
protein (MBP), and a- and b-casein; Sigma-Aldrich), and the
recombinant SR proteins used as phosphoacceptor substrates were
added to the reaction. The recombinant SR proteins were purified
via chromatography as described above. For negative control,
purified MaBP-tag alone was used for substrate in the kinase
activity assays. An additional negative control, in which the
parasite lysate was replaced by the same volume of PBS (PBS
control), was used to exclude unspecific phosphorylation of
reaction components. Reactions were incubated at 37uC for 1 h
under constant agitation and terminated by addition of reducing
Laemmli buffer for 10 min at 95uC. Samples were separated on
12% SDS-PAGE, dried by means of vacuum gel drying and
exposed to X-ray films for 48–90 h at 220uC. For quantification
of inhibition of phosphorylation, the mean grey values (MGV) of
the phosphorylation bands were measured using the ImageJ
program. Background values were subtracted and the MGVs for
the DMSO control were set to 100% to calculate the relative
MGV (rMGV).
Malstat assay
The CLK inhibitors were screened for antiplasmodial activity
against P. falciparum strain 3D7 at concentrations of 6.4 nM–
500 mM, using the Malstat assay as described [39–41]. Sorbitol-
synchronized ring stages were plated in triplicate in 96-well plates
(200 ml/well) at a parasitemia of 1% in the presence of the
compounds. Chloroquine (diphosphate salt, Sigma-Aldrich; dis-
solved in double-distilled water) served as positive control in all
experiments. Incubation of parasites with DMSO alone at a
concentration of 0.5% vol. was used as negative control. Treated
parasites were cultivated in vitro for 72 h, resuspended and
aliquots of 20 ml were transferred to a new plate. 100 ml of the
Malstat reagent was added to initiate the conversion of lactate to
pyruvate by parasite lactate dehydrogenase (pLDH) in the
Effect of CLK Inhibition on Malaria Parasites
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presence of the co-factor APAD. The reduced APAD (APADH)
formed during the reaction is used for the assessment of pLDH
activity by adding a 20 ml of a mixture of NBT (nitro blue
tetrazolium)/Diaphorase (1:1; 1 mg/ml stock each) to the Malstat
reaction. The APADH and the NBT form a purple coloration and
the absorbance was measured at OD (630 nm). Each compound
was tested 2 to 4 times, and the IC50 values were calculated from
variable-slope sigmoidal dose-response curves using the GraphPad
Prism program version 5.
Stage of inhibition assay
The compounds CHX, KH-CARB-10, KH-CARB-11, KH-
CARB-13xHCl, and gea-27 were added to synchronized ring
stage parasites (T0) in IC50 (0.8, 7.5, 6.1, and 4.0 mM, respectively)
and IC80 (4.0, 37.0, 30.0, and 20.0 mM respectively) concentra-
tions, and blood smear samples were taken at 24, 36, 48, and 60 h
of incubation with CHX and at 24 h of incubation in case of the
other inhibitors. The numbers of ring stages, trophozoites and
schizonts as well as of dead parasites were counted for a total
number of 100 infected erythrocytes for each setting.
Gametocyte toxicity assay
P. falciparum NF54 parasites were grown at high parasitemia to
favour gametocyte formation. Upon appearance of stage II
gametocytes, 1 ml of culture was aliquoted in triplicate in a 24-
well plate in the presence of compounds at the respective IC50
concentrations. The gametocytes were cultivated for 7 d and the
medium was replaced daily. For the first 48 h of cultivation, the
gametocytes were treated with CLK inhibitors; subsequently the
medium was compound-free. At day 7, Giemsa-stained blood
smears were prepared and the gametocytemia was evaluated by
counting the numbers of gametocyte stages IV and V in a total
number of 1000 erythrocytes. Negative controls were performed
with 0.5% vol. of DMSO. Chloroquine was used as additional
negative control, while epoxomicin was used as positive control
[41]. Two independent experiments in triplicates were conducted
and the mean gametocytemia was calculated for each compound.
Data from the experimental cultures was normalized to the
DMSO control, which was set to 100%, and the student’s t-test
was performed for statistical analysis using the Microsoft Excel
2010 program.
Exflagellation inhibition assay
A volume of 100 ml of mature NF54 gametocyte cultures was
pre-incubated with CLK inhibitors in concentrations ranging
between 0.1 mM-1 mM for 15 min at 37uC. Each sample was then
transferred to RT and 100 mM of xanthurenic acid was added for
activation. After another 15 min, the numbers of exflagellation
centers were counted in 30 optical fields using a Leica DMLS
microscope by 400-fold magnification. Two independent exper-
iments were performed in duplicates and the inhibition of
exflagellation was calculated as a percentage of the number of
exflagellation centers in compound-treated cultures in relation to
the number of exflagellation centers in untreated controls with
0.5% vol. of DMSO. The IC50 values were calculated from
variable-slope sigmoidal dose-response curves using the GraphPad
Prism program version 4.
Figure 3. Subcellular localization of PfCLK-3 and PfCLK-4 in the
blood and gametocyte stages. Mixed asexual blood stage cultures
containing trophozoites (TZ) and schizonts (SZ) and mature gametocyte
(GC) cultures were fixed with methanol and prepared for IFA, using rat
antisera against PfCLK-3 and mouse antisera against PfCLK-4 (green).
The parasite nuclei were highlighted by Hoechst staining (blue). The
asexual blood stages were labelled with rabbit antisera against PfMSP-1
and gametocytes with rabbit antisera against Pfs230 (red). Bar, 5 mm.
doi:10.1371/journal.pone.0105732.g003
Figure 4. Expression of PfCLK-3 and PfCLK-4 in the cytoplasmic
and nuclear fractions of blood stage parasites. Western-blot
analyses on lysates of mixed blood stage parasites (BSP) as well as of
nuclear pellet (NP) or cytoplasmic fraction (CF) of BSP using rat antisera
against PfCLK-3 or mouse antisera against PfCLK-4 detected the full
length protein bands for PfCLK-3 and PfCLK-4 of approximately 80 and
150 kDa, respectively. For PfCLK-4, two additional protein bands of
approximately 100 and 70 kDa are present. No proteins were detected
by the anti-PfCLK antisera in lysates of non-infected erythrocytes (EC).
Immunoblotting with sera from non-immunized rat (NRS) or mouse
(NMS) did not result in the labelling of any protein bands.
doi:10.1371/journal.pone.0105732.g004
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Results
The PfCLKs show homologies with yeast SR protein
kinase Sky1p
The genome of P. falciparum encodes four proteins clustering
within the CLK family, termed PfCLK-1-4 [9]. In PfCLK-1-3, the
predicted kinase catalytic domains are located at the C-terminus;
the catalytic domain of PfCLK-4, on the other hand, starts at the
N-terminus and spans more than half of the protein (see Fig. 1A).
While in silico analysis of gene sequences previously revealed two
nuclear localization signals for PfCLK-1 and one for PfCLK-2
upstream of the C-terminal catalytic domains [11], PfCLK-3 and
PfCLK-4 do not comprise such signals.
The catalytic domain sequences of the four PfCLKs showed
homologies with the Saccharomyces cerevisae SR protein kinase
Sky1p [42], as was shown by sequence alignment (Fig. S1) [11].
The sequence DLKPxN with the conserved Aspartate 126 is
present and is considered to be the catalytic base. The loop at
positions 169–193 signifies the activation segment, starting with
Aspartate 169 and ending with sequence APE in PfCLK-1,
PfCLK-3, PfCLK-4 and SPE in PfCLK-2 and Sky1p. The ATP-
binding domain GXGXXG is present at positions 8–13 for
PfCLK-1 and GXGXXS for PfCLK-3, PfCLK-4 and Sky1p, but
is missing in PfCLK-2. Furthermore, sequence alignment with
Sky1p revealed matches between substrate binding residues of the
kinases with the substrate binding site of Sky1p, including Arginine
187, Tyrosine 189, Arginine 190 and Glutamate 215 (Fig. S1).
The PfCLKs and the SR proteins are expressed in the
blood stages of P. falciparum
Previous studies showed that PfCLK-1 and PfCLK-2 are
present in the asexual blood stages and in gametocytes of P.
falciparum. Here, PfCLK-1 can be found in the nucleus of
trophozoites, while in schizonts and gametocytes the kinase is
present in nucleus and cytoplasm. PfCLK-2 is detected in the
nucleus and the cytoplasm of the asexual blood and gametocyte
stages [11]. Via IFA we now show that PfCLK-3 and PfCLK-4 are
mainly present in the nucleus of trophozoites, while in schizonts
and gametocytes both kinases are primarily located in the
cytoplasm (Fig. 3). Particularly for PfCLK-3 a rim-associated
labelling pattern was observed in the latter stages. In the IFAs, the
asexual blood stage parasites and the gametocytes were highlight-
ed by labelling of plasmalemma-associated proteins, i.e. PfMSP-1
and Pfs230, respectively.
The presence of PfCLK-3 and PfCLK-4 in the nucleus and
cytoplasm of blood stage parasites was subsequently confirmed by
Western blot analysis. Immunoblotting of blood stage parasite
lysate with rat anti-PfCLK-3 antisera labelled the full length kinase
of approximately 80 kDa (Fig. 4). Full length PfCLK-3 was further
detected, when nuclear pellet and cytoplasmic fractions were
immunoblotted with the respective antibody. Immunoblotting of
the blood stage lysate as well as nuclear pellet and cytoplasmic
fractions with mouse anti-PfCLK-4 antisera, on the other hand,
resulted in the labelling of three bands, the full-length kinase band
of approximately 160 kDa and two additional bands with
molecular weights of approximately 100 and 70 kDa, which
might represent processing products (Fig. 4). Lysate of non-
infected erythrocytes were used for control, and no protein bands
were detected after immunoblotting with the respective anti-
PfCLK antisera. Similarly, no protein bands were detected, when
the blood stage parasite lysates were immunoblotted with sera of
non-immunized animals (Fig. 4).
We then investigated the blood stage-specific localization of
three previously identified SR proteins, i.e. PfSRSF12, PfSFRS4
Figure 5. Subcellular localization of the SR proteins in the
blood and gametocyte stages. Mixed asexual blood stage cultures
containing trophozoites (TZ) and schizonts (SZ) and mature gameto-
cyte (GC) cultures were fixed with paraformaldehyde and prepared for
IFA, using mouse antisera against PfSRSF12, PfSFRS4 and PfSF-1 (green).
The parasite nuclei were highlighted by Hoechst staining (blue). The
asexual blood stages were labelled with rabbit antisera against PfMSP-1
and gametocytes with rabbit antisera against Pfs230 (red). Bar, 5 mm.
doi:10.1371/journal.pone.0105732.g005
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and PfSF-1 (see Fig. 1B) [14]. Transcriptome data available at
PlasmoDB point to a predominant transcript expression in the
trophozoite stage for all three SR proteins [17]. In accord with
these data, IFAs, using respective antisera raised in mice, detected
the three SR proteins in the trophozoite nucleus (Fig. 5, top rows).
An additional minor labelling was observed in the nuclei of the
schizont stages (Fig. 5, center rows). Furthermore, PfSRSF12 and
PfSF-1 were present in the nucleus of gametocytes, while PfSFRS4
was not detected in these stages (Fig. 5, bottom rows). In depth
analysis of the localization of the SR proteins in transforming
trophozoites (2-nuclei stage) confirmed that the splicing factors are
present in distinct areas of the parasite nuclei, while they cannot be
detected in the cytoplasm of the parasites (Fig. 6).
We subsequently performed co-localization experiments be-
tween the three SR proteins, using the respective mouse antisera,
and PfCLK-1, using antisera raised in rabbit. The co-localization
experiments confirmed that the SR proteins are solely present in
the nuclei, while in the early schizont stage, PfCLK-1 is present
both in the parasite nuclei and the cytoplasm. Co-localization of
PfCLK-1 with the three SR proteins can be detected in distinct
nuclear regions (Fig. S2A).
In a subsequent step, the numbers of parasites positive for the
PfCLKs and the SR proteins were determined. When blood stage
schizonts were highlighted by immunolabelling with anti-MSP-1
antibody or by Hoechst nuclear staining, 9961.0% of schizonts
labelled for PfCLK-1-3 or PfSF-1, 9662% of schizonts labelled for
PfCLK-4, 9262.8% of schizonts labelled for PfSFRS4, and
9460.6% of schizonts labelled for PfSRSF12. Further 10060.9%
of Pfs230-positive gametocytes labelled for PfCLK-1, 9861.1% of
gametocytes labelled for PfCLK-2, 8462.3% of gametocytes
labelled for PfCLK-3, 9461.1% of gametocytes labelled for
PfCLK-4, 9661.6% of gametocytes labelled for PfSF-1, and
9660.6% of gametocytes labelled for PfSRSF12.
No labelling was detected, when serum of non-immunized mice
was used in the IFAs. Further, IFAs using mouse antisera directed
against the GST- and MaBP-tags did not result in any labelling of
the blood stage parasites (Fig. S2B).
The PfCLKs mediate phosphorylation of SR proteins
We aimed to determine the phosphorylation activity of
precipitated PfCLKs obtained from asexual blood stage cultures.
As described previously, immunoblotting of blood stage parasite
lysate with mouse or rabbit anti-PfCLK-1 antisera resulted in a
processed kinase band of approximately 60 kDa (Fig. S3A), while
mouse anti-PfCLK-2 antisera detected a full-length protein band
at 150 kDa [11]. Furthermore, immunoblotting of blood stage
parasite lysate with rat anti-PfCLK-3 or mouse anti PfCLK-4
antisera detected full-length kinase bands of approximately 80 and
160 kDa, respectively (see above, Fig. 4). When the PfCLKs were
immunoprecipitated from the blood stage parasite lysate using the
respective antisera, the full-length kinase bands for PfCLK-2-4
were detected, when the same antisera were used for immuno-
blotting (Fig. S3B). It was not possible, however, to detect the
processed 60 kDa band typical for PfCLK-1, since protein bands
of this molecular weight interfere with the protein band of the
heavy chain of the precipitating antibody, which is running as a
smear at a molecular weight of approximately 55 kDa (Fig. S3B).
For control, sera of non-immunized animals were used in
immunoblotting and no precipitating protein bands (with the
exception of the heavy chain antibody band) were detected (Fig.
S3C). Similarly, no precipitated protein bands were detected,
when mouse antisera directed against the endoplasmic reticulum-
associated protein Pf39 [43] or the proteasome subunit alpha 5
(Pfalpha-5) [37] were used for immunoblotting (data not shown).
The immunoprecipitated PfCLK proteins were used in the
kinase activity assays as described previously [11], adding as
Figure 6. Localization of the SR proteins in the parasite nucleus. Transforming trophozoites (2-nuclei stages) were prepared for IFA as
described in Fig. 5 and the localization of the SR proteins was investigated in the Hoechst-positive parasite nuclei. Bar, 5 mm.
doi:10.1371/journal.pone.0105732.g006
Effect of CLK Inhibition on Malaria Parasites
PLOS ONE | www.plosone.org 7 September 2014 | Volume 9 | Issue 9 | e105732
exogenous substrates histone H1, MBP, or a/b casein, as well as
radiolabelled [c-32P] ATP. All PfCLKs were associated with
phosphorylation activity of all three substrates (Fig. 7, upper
panel). Recombinant PfPK6 was used as a positive control [38]
and also exhibited strong phosphorylation activity of the three
exogenous substrates. As negative control, the assay was
performed without precipitated kinases (PBS control). Coomassie
blue staining of radiolabelled gels were used for loading control
(Fig. 7, lower panel).
Subsequently we wanted to determine if the plasmodial SR
proteins PfSRSF12, PfSFRS4, and PfSF-1 function as in vitro
substrates for the immunoprecipitated PfCLKs. Peptides compris-
ing the RS-rich domains were bacterially expressed as tagged
fusion proteins. For PfSF-1, two recombinant proteins were
expressed, comprising either the N-terminal part with the RS-rich
domain or the C-terminal part, which includes the RNA
recognition motif (see Fig. 1B). The SR proteins were purified
via affinity chromatography before deploying these as substrates in
the above described kinase activity assays. The assays revealed that
recombinant PfSRSF12 was phosphorylated by anti-PfCLK-2 and
anti-PfCLK-3 precipitate (Fig. 8A, upper panel), whilst recombi-
nant PfSFRS4 was phosphorylated by all PfCLK-specific precip-
itates. When the immunoprecipitates were incubated with the N-
terminal fraction of PfSF-1, phosphorylation signals were detected
with the exception of the PfCLK-3 precipitate. In contrast, no
phosphorylation signals were detected, when the immunoprecip-
itates were incubated with the C-terminal part of PfSF-1, which
did not comprise the RS-rich motif (Fig. 8B, upper panel). Purified
MaBP-tag was used as a substrate instead of the recombinant SR
proteins and served as a negative control in the assays, and no
phosphorylation of MaBP was observed (Fig. 8C, upper panel).
Coomassie blue staining of radiolabelled gels was used as a loading
control (Fig. 8, lower panels).
CLK inhibitors impair the phosphorylation activity of the
PfCLKs
Previous attempts to knock-out the pfclk genes via single cross-
over gene disruption in order to study the function of the PfCLKs
was unsuccessful [11,15]. However, locus modification (tagging
each sequence with a Myc epitope to the 39-end) was achieved
[11,15] (S. Kern, G. Pradel, unpublished observations), demon-
strating that the genomic loci are accessible for recombination.
Figure 7. Phosphorylation of exogenous substrates by immunoprecipitated PfCLKs. Kinase activity assays were deployed to detect
phosphorylation of the substrates histone H1, MBP and a/b casein (,33, 18, and 28/34 kDa, respectively; indicated by arrows) by the four
immunoprecipitated PfCLKs (autoradiogram, upper panel), using the PfCLK-specific respective mouse, rabbit or rat antisera. Assays without
precipitated proteins (PBS control) were used for negative controls. Recombinant protein kinase 6 (rPK6) was used for positive control. Coomassie
blue staining (lower panel) of radiolabelled SDS-gels was used as a loading control.
doi:10.1371/journal.pone.0105732.g007
Effect of CLK Inhibition on Malaria Parasites
PLOS ONE | www.plosone.org 8 September 2014 | Volume 9 | Issue 9 | e105732
Figure 8. Phosphorylation of plasmodial SR proteins by immunoprecipitated PfCLKs. A. Kinase activity assays were deployed to detect
phosphorylation of recombinant PfSRSF12 and PfSFRS4 (,73 and 65 kDa, respectively; indicated by arrows) by two or more of the PfCLKs
(autoradiogram; upper panel). B. The N-terminal part (,95 kDa; indicated by arrows), but not the C-terminal part (86 kDa) of recombinant PfSF-1 was
phosphorylated by immunoprecipitated PfCLKs. An additional phosphorylation signal of truncated N-terminal PfSF-1 was visible at approximately
60 kDa. C. MaBP-tag alone (43 kDa) as substrate was used as negative control. Shown here is an assay using PfCLK-3-specific immunoprecipitate,
similar results were obtained with immunoprecipitates of other PfCLKs (not shown). Coomassie blue staining (lower panels) of radiolabelled SDS gels
was used as a loading control.
doi:10.1371/journal.pone.0105732.g008
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These data lead to the conclusion that the PfCLKs have essential
roles for the parasite blood stages, prohibiting the survival of
PfCLK knock-out mutants.
In order to functionally analyse the role of the PfCLKs for the
P. falciparum blood and sexual stages, we aimed at a chemical
inhibition of the kinases. We screened a small compound library of
63 human CLK inhibitors [22,44] for antiplasmodial activity,
using the Malstat assay (Table S2). We identified five compounds,
i.e. the oxo-b-carbolines KH-CARB-10, KH-CARB-11, KH-
CARB-13xHCl, and the aminopyrimidines C-117 and gea-27,
which exhibited half-maximal growth inhibitory concentrations
(IC50) in the low micromolar range (Table 1). We further screened
the antiseptic chlorhexidine (CHX) for antiplasmodial activities,
because it has previously been reported to act on P. falciparum
[45] as well as on CLKs [46,47]. In the Malstat assay, CHX
exhibited an IC50 value in the nanomolar range (Table 1).
In order to confirm that the inhibitors act on the PfCLKs, we
tested these for their inhibitory effect on PfCLK-mediated
phosphorylation. Blood stage parasites were incubated with the
three inhibitors gea-27, KH-CARB-13xHCl, and CHX at IC50
concentrations for 12 h. DMSO was used for negative control.
The kinase activity assays were conducted as described above,
using MBP for substrate. The signals for phosphorylated MBP
were detected by autoradiography and the rMGV of the
phosphorylation signals was measured. The assays revealed a
reduction in the rMGV by 24.1–76.4%, when the parasites were
incubated with the inhibitors prior to the assay (Fig. 9A). For gea-
27, no effect on the phosphorylation activity of PfCLK-4 was
detected.
As control, the assays were carried out on immunoprecipitates
using antisera against the CaM-dependent protein kinase-related
protein PfPKRP [15]. The 295 kDa PfPKRP has an N-terminal
catalytic domain (Fig. S4A) and is a homolog of the P. berghei
PKRP, which plays a role for parasite transmission to the
mosquito [48]. Because protein expression of PfPKRP has not
yet been described in the P. falciparum blood stages, we tested the
antisera in IFA prior to use in the kinase activity assays. PfPKRP
was detected in the asexual blood stage schizonts (Fig. S4B). In
gametocytes, the kinase is present throughout maturation from
stage II to stage V, and here is localized in the cytoplasm (Fig. S4B,
C). Because PfPKRP was annotated as a CaM-dependent kinase,
the experiments were conducted with and without addition of
50 mM CaM. In the presence of CaM, the PfPKRP-specific
immunoprecipitate was able to phosphorylate MBP (Fig. 9B). In
reactions lacking CaM, no specific phosphorylation of MBP was
detected, indicating that the activity of PfPKRP is CaM-
dependent. Noteworthy, no differences in the MBP phosphoryla-
tion signals were detected between precipitates of parasites treated
with the CLK inhibitors and DMSO-treated control parasites
(Fig. 9B). The PfPKRP control experiment on the one hand
demonstrates that the CLK inhibitors do not inhibit PfPKRP, and
on the other hand proves that the decrease in the phosphorylation
signal of the PfCLK-specific precipitates seen after treatment with
the CLK inhibitors is not caused by a general reduced viability of
the inhibitor-treated parasites. As a second negative control,
antisera against Pf39 [43] was used for immunoprecipitation.
Pf39-specific precipitate did not phosphorylate MBP, showing that
in the absence of immunobound kinases, the parasite precipitate
has no phosphorylation activity (Fig. 9C).
PfCLK inhibitors block schizogony and sexual stage
development
After confirming the PfCLK-specific inhibitory activity, we
aimed to determine at which developmental stage the parasites
become arrested by the inhibitors. This was investigated using the
stage-of-inhibition assay as previously described [41,49]. The most
active inhibitor, CHX, was given to the synchronized ring stage
parasites (T0) at approximate IC50 and IC80 concentrations and
Giemsa smears were taken at 24–60 h of CHX incubation. The
Giemsa smears showed that the CHX-treated parasites developed
to trophozoites but that the majority of the parasites died before
entering the schizont stage. While a few parasites escaped the
killing during the first replication cycle at the given concentrations,
these died during trophozoites-to-schizont transformation of the
second replication cycle (Fig. 10A). To investigate, if a similar
killing mechanism applies to the other CLK inhibitors, we
determined the stage of inhibition for KH-CARB-10, KH-
CARB-11, KH-CARB-13xHCl, and gea-27 after 24 h of incuba-
tion of parasites with the respective compound at the approximate
IC50 and IC80 concentrations. In all cases, the blood stage
parasites died, once they entered schizogony (Fig. 10B). The
lowest killing effect at 24 h of compound incubation was observed
for gea-27, here schizonts were observed in parasite samples
treated with IC50 and IC80 concentrations of the compound
(Fig. 10B).
Once the antiplasmodial activity of the CLK inhibitors was
demonstrated, we investigated their effect on the sexual transmis-
sion stages of P. falciparum. Firstly, the gametocytocidal activity of
the compounds was tested, using the gametocyte toxicity test as
previously described [41]. The CLK inhibitors significantly
reduced the maturation of gametocytes by 40–60% compared to
DMSO-treated controls. KH-CARB-11 showed the highest
gametocytocidal activity with a reduction of mature gametocytes
by 62.5% (Fig. 10C). Chloroquine was used as a negative control,
while the proteasome inhibitor epoxomicin was used as a positive
control. The CLK inhibitors further impaired exflagellation of P.
Table 1. Antiplasmodial and transmission blocking activities of the CLK inhibitors.
Compound Class IC50 (Malstat) [mM] IC50 (EIA) [mM]
KH-CARB10 oxo-b-carboline 7.262.40 14.063.72
KH-CARB11 oxo-b-carboline 6.161.09 15.860.84
KH-CARB13xHCl oxo-b-carboline 4.461.84 13.866.22
C-117 aminopyrimidine 7.562.76 67.5613.03
gea-27 aminopyrimidine 5.260.35 154.2656.43
CHX antiseptic 0.660.20 19.860.93
Chloroquine 4-aminoquinoline 0.0460.013 N/A
doi:10.1371/journal.pone.0105732.t001
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falciparum, as demonstrated by exflagellation inhibition assay.
The strongest inhibitory activities on male gametogenesis were
shown for KH-CARB-10, KH-CARB-11, and KH-CARB-
13xHCl with IC50 values between 10–20 mM (Table 1). The
combined data indicate that the PfCLKs play essential roles for
erythrocytic schizogony, gametocyte differentiation and gameto-
genesis.
Figure 9. Effect of CLK inhibitors on MBP phosphorylation. A. Kinase activity assays were deployed to detect MBP phosphorylation by
inhibitor-treated immunoprecipitated PfCLKs. The parasites were incubated with the CLK inhibitors at IC50 concentrations or 0.5% vol. DMSO for 12 h
prior to the assays. The phosphorylation signals were measured as rMGV (MGV of DMSO set to 100%). B. PfPKRP-specific immunoprecipitate
phosphorylates MBP in the presence but not absence of 50 mM CaM, independent from prior incubation of the parasites with the CLK inhibitors. C.
Pf39-specific immunoprecipitate was used as a negative control in the assays.
doi:10.1371/journal.pone.0105732.g009
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Discussion
CLKs are dual specificity protein kinases that phosphorylate SR
proteins involved in pre-mRNA processing. These, when not in
action, reside in the nuclear speckles, but shuttle between the
nucleus and the cytoplasm during splicing. The activity of SR
proteins is controlled by their phosphorylation status, and a
change in phosphorylation changes the ability of SR proteins to
interact with other proteins. Because the choice of splice sites
during pre-mRNA processing is regulated by the concentration
Figure 10. Effect of CLK inhibitors on blood stage parasites. A. Stage of growth inhibition of asexual blood stages between 12–60 h of CHX
treatment. CHX at approximate IC50 and IC80 concentrations or 0.5% vol. of DMSO was added to synchronized parasites at the ring stage. Giemsa
stained blood smears were prepared at six time points between 0–60 h of incubation with CHX and the numbers of ring stages, trophozoites,
schizonts and dead parasites were counted. Histograms indicate the percentages of developmental stages present in the respective blood smears. B.
Parasites were treated with CLK inhibitors as described above and the stage of growth inhibition was determined at 24 h of compound incubation. A
total number of 100 parasites were counted in A and B for each condition. C. Compounds at IC50 concentrations or 0.5% vol. of DMSO were added to
stage II gametocyte cultures for two days. After seven days, the numbers of stage IV and V gametocytes were counted in a total of 1000 erythrocytes
and correlated to the gametocyte numbers of DMSO control (set to 100%). *, significant reduction of gametocyte numbers (p,0.001, student’s t-
test). Epoxomicin was used as positive and chloroquine was used as a negative control.
doi:10.1371/journal.pone.0105732.g010
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and the phosphorylation status of the SR proteins, CLKs play an
indirect role in governing splice site selection emphasizing their
importance for AS (reviewed in [50]).
The four PfCLKs of P. falciparum show homologies with yeast
Sky1p, a kinase involved in mRNA splicing and mRNA transport
[42,51]. The kinases are abundantly expressed in the asexual
blood stages of P. falciparum. In the trophozoites, the PfCLKs are
present in the nucleus, where they co-localize with the plasmodial
SR proteins PfSRSF12, PfSFRS4 and PfSF-1. During schizogony
and gametocyte development, the kinases relocate from the
nucleus to the parasite cytoplasm. Noteworthy, PfCLK-1 and
PfCLK-2 possess nuclear localization signal sites and are predicted
to be localized in the parasite nuclear speckles. A nucleus-
cytoplasm passage was demonstrated for both kinases on the
ultrastructural level [11]. The combined immunohistological data
let us conclude that the PfCLKs accompany splicing factors during
the shuttle between nucleus and cytoplasm or phosphorylate
substrate in the cytoplasm in dependence on the developmental
stage of the blood stage parasite.
In previous studies we were unable to generate P. falciparum
parasites with disrupted pfclk loci, while the insertion of a tagging
sequence was possible for all pfclk genes [11,15] (S. Kern, G. Pradel,
unpublished observation). The inability to knock out a kinase gene
locus, together with the ability to modify the allele in a way that does
not cause loss-of-function of the gene product, are strongly indicative
of an essential role during the asexual blood cycle. The inability to
disrupt a single pfclk gene further demonstrates that none of the
PfCLKs can compensate for the loss of another PfCLK, indicating
that the kinases have non-redundant functions. This is in accordance
with the findings that multiple kinases are involved in SR protein
phosphorylation in different cellular compartments. For example
human ASF becomes phosphorylated by SRPK1 and SRPK2 in the
cytosol, thus facilitating its nuclear import and accumulation in the
nuclear speckles. There, a family of CLKs hyperphosphorylates the
SR protein, mediating its release from the nuclear speckles and
relocation to the region, in which splicing events occur [52–54].
Noteworthy, in the rodent malaria model P. berghei, the pbclk4 gene
(termed srpk1 in this study) can be knocked out, resulting in impaired
exflagellation [55]. In accordance with these findings we recently
showed that PfCLK-4 is abundantly expressed in gametocytes, but
down-regulated once gametogenesis has ceased [56], indicating that
PfCLK-4 has a particular function during parasite transmission from
the mammalian host to the mosquito vector.
We identified three plasmodial SR proteins, PfSRSF12,
PfSFRS4, and PfSF-1, which function as substrates for the
PfCLKs in vitro, and the four kinases appear to have different
phosphorylation preferences for the three SR proteins. The three
SR proteins are predominantly present in the nucleus of blood
stage parasites, where they co-localize with the PfCLKs, and
PfSRSF12 and PfSF1 can further be detected in gametocytes.
Additionally, PfCLK-4 (SRPK1) was previously reported to
phosphorylate AS factor SR1 [13]. For all of the plasmodial SR
proteins, phosphorylation sites have been identified (Table S3) and
the proteins are phosphorylated in vivo, as determined in the P.
falciparum schizont stages [15,57–59]. Noteworthy, a peptide of
PfSF-1, which comprises the RNA recognition motifs, but not the
RS-rich motifs, cannot be phosphorylated by any of the four
PfCLKs, demonstrating the importance of the RS-rich motif for
the interaction between SR protein and kinase.
Due to the inability to knock-out the pfclk genes by reverse
genetics, we aimed to chemically knock-out the PfCLKs for
functional studies. We identified five human CLK inhibitors as
well as the antiseptic CHX as antiplasmodial agents and
demonstrated their inhibitory effect on the PfCLKs via kinase
activity assay. The inhibitors act on the Plasmodium parasites in
the low micromolar range. While we demonstrate that the CLK
inhibitors have no activity against the calmodulin-dependent
kinase PfPKRP, other off-target effects of the inhibitors can
currently not be excluded.
Morphological analyses on drug-treated parasites showed that
the inhibitors arrest the parasites during the trophozoites-to-
schizont transition. Furthermore, the inhibitors impaired gameto-
cyte development and exflagellation. Particularly the KH-CARB
inhibitors acted on blood stage replication and on exflagellation in
similar concentrations. These data indicate that the PfCLKs have
an important role during schizogony and are further crucial
during parasite transmission from the human to the mosquito.
These findings make them potential candidates as targets for
antimalarials with transmission blocking properties.
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systematic functional analysis of Plasmodium protein kinases identifies essential
regulators of mosquito transmission. Cell Host Microbe 8: 377–387.
56. Ngwa CJ, Scheuermayer M, Mair GR, Kern S, Brügl T, et al. (2013) Changes in
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